Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
NEW YORK, Feb. 12, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Nobilis Health Corp. (“Nobilis”) (NYSE MKT:HLTH) between April 2, 2015 and January 6, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of Texas on behalf of Nobilis shareholders. If you purchased or otherwise acquired Nobilis securities between April 2, 2015 and January 6, 2016, your rights may be affected by this action. To get more information go to:
http://zlk.9nl.com/nobilis-health
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period defendants issued materially false and misleading statements to investors and/or failed to disclose that: (1) Nobilis’ financial statements contained numerous errors concerning the classification of warrants and options, business combination accounting, share-based compensation, and other financial and operating results; (2) Nobilis overstated its net income for the year ended December 31, 2014 by more than $4 million; (3) Nobilis overstated its net income for the quarter ended March 31, 2015 by more than $3.27 million; and (4) as a result, defendants’ statements about Nobilis’ business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
If you suffered a loss in Nobilis you have until March 21, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
